Cook Medical is introducing European head and neck surgeons and otolaryngologists to its line of minimally invasive devices at the 2nd meeting of the European Academy of OtoRhinoLaryngology and Head Neck/Surgery (EAORL-HNS).
Cook Medical launches a new fully-retractable 0.035 inch embolization coil, intended for peripheral arterial and venous embolization. Embolization is a nonsurgical, minimally invasive procedure performed by a physician to block or reduce blood flow in arteries and veins.
Cook Medical's Flexor Parallel Rapid Release Ureteral Access Sheath which is the only Food and Drug Administration (FDA) approved ureteral access sheath that has two options for placement is now being introduced to the US market.
Riverside Methodist Hospital in Columbus, Ohio, USA, is treating the first patient with Cook Medical's Zilver PTX drug-eluting peripheral stent just weeks after the US Food and Drug Administration (FDA) approved the device.
Cook Medical receives US Food and Drug Administration (FDA) marketing approval for the first devices in its Zilver PTX Drug-Eluting Peripheral Stent portfolio, company officials reported today. It’s the first time the FDA has approved a drug-eluting stent to treat blockages in a peripheral artery.
Cook Medical reports that three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease demonstrates 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent.
Following Health Canada approval, Cook Medical is making the Zilver Vena Venous Self-Expanding Stent available to physicians across Canada at the 2012 Annual Meeting of the Canadian Society for Vascular Surgery.
Cook Medical launches its new Otolaryngology/Head and Neck Surgery (OHNS) clinical division to bring the benefits of the company's devices for non-surgical procedures to a new group of physicians and the patients they treat.
Three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease indicates that Cook Medical's paclitaxel-eluting peripheral vascular stent demonstrated 83.0 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479 patient study.
In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical receives PMDA approval to sell the Zilver PTX Drug-Eluting Peripheral Stent in Japan.
Hospitals around the USA are going to receive three more years of access to a specialty urology agreement with an extensive line of specialty urology products at special pricing after Cook Medical and the Premier healthcare alliance renewed their contract to provide Cook's urology products to more than 2,500 hospitals.
Cook's Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee.
Cook Medical is launching the endogo HD Portable Endoscopic Imaging System by Envisionier Medical Technology which offers the ability to capture, store and share endoscopic images, making it possible for doctors to share information with patients instantly, simplify collaboration between colleagues and potentially reduce costs by eliminating the need for repeat procedures.
In an effort to provide surgeons and nurses with an advanced tool to better monitor blood flow during free flap procedures, Cook Medical launches the Doppler DP-M350 Blood Flow Monitor, a medical device at the forefront of transplant and reconstructive surgery.
Cook Medical is introducing a new histology needle for endoscopic ultrasound (EUS) which gives physicians the ability to retrieve tissue samples from hard-to-reach regions within or adjacent to the GI tract with a minimally invasive procedure.
Cook receives three new contracts with Premier Purchasing Partners, the group-purchasing organization of national health care alliance, Premier, and will see patients at more than 2,400 hospitals and 70,000 health care facilities being able to access Cook Medical’s line of diagnostic and interventional radiology products, including peripheral vascular and biliary stents, effective February 1, 2011.
An investigational drug-eluting stent (DES) from Cook Medical is showing sustained primary patency at two years compared to data collected at one year in the device’s prospective, randomized study, according to data presented at the ISET 2010 International Symposium on Endovascular Therapy.
Study investigators are reporting initial data from Cook Medical’s REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company’s balloon-expandable renal stent for the treatment of renal artery stenosis.
Surgeons and physicians can now explore cutting-edge treatment options and best practices on Cook Medical’s new ′Leg Therapies’ microsite, an online destination to advance the treatment of leg diseases like peripheral arterial disease (PAD) and the more advanced stage critical limb ischemia (CLI).
Cook Medical expands the company’s Spectrum Turbo-Ject line of antibiotic impregnated peripherally inserted central venous catheters (PICCs) to treat a wider range of patient needs and is in response to increased demand for technology to help prevent potentially fatal catheter-related bloodstream infections (CRBSIs).
Two independent clinical studies, presented separately at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco, report that Cook Medical's BIGopsy Backloading Biopsy Forceps' ability to obtain larger tissue samples for biopsy can lead to an improved ability to diagnose the cause of suspicious ureteral or kidney lesions.
The long-term success of Cook Medical's Resonance Metallic Ureteral Stent in providing drainage for patients with both benign and malignant upper urinary tract obstructions is demonstrated by a 29-month clinical study (Ref 1) presented at the 2010 Annual Meeting of the American Urological Association (AUA).
More than 40,000 US health care providers are to gain access to special pricing and terms for an advanced biologic graft for soft tissue repair through a contractual relationship between Cook Medical and Novation, the leading health care supply company for VHA, University HealthSystem Consortium (UHC) and Provista.
European physicians placing inferior vena cava (IVC) filters to prevent patient injury and death from pulmonary embolism (PE) are now able to use a delivery system from Cook Medical that increases the efficiency and safety when placing these potentially life-saving filters.
More than 1,250 patients worldwide have been treated with the Zenith TX2 TAA Endovascular Graft with Pro-Form, the first-of-its-kind device from Cook Medical designed specifically to repair thoracic aortic aneurysms (TAAs) in anatomies with tight arches as well as conventional cases.